GPT and metabolic dysfunction-associated steatotic liver disease: Newsome et al. (2019) conducted a post hoc analysis using data from two randomized, double-blind trials regarding the effects of semaglutide on alanine aminotransferase (ALT) and high sensitivity C reactive protein (hs CRP) in patients who were at risk for NAFLD.